Low-dose THC/CBD helps restless legs in MS — 1 year

Credibility

Interest

Share:2 min read

Key Takeaway

A low-dose THC/CBD medicine reduced the severity of restless legs symptoms in people with MS and helped them stay asleep better at night.

What They Found

Researchers gave a small daily dose of THC (a cannabis chemical that can calm nerves) and CBD (a cannabis chemical that may reduce side effects) to people with restless legs syndrome (RLS), most of whom had MS. After one and three months, people reported much less RLS symptoms on a standard questionnaire, and many still had improvement after one year. Nighttime waking after falling asleep (how long people stayed awake during the night) decreased, so people spent less time awake in the middle of the night. The time it took to fall asleep and overall sleep efficiency (the percent of time in bed spent actually sleeping) did not change much. Most participants had normal iron tests and mild disability from MS at the start, so these results come from a group with relatively mild to moderate MS.

Who Should Care and Why

People with MS who also have restless legs may benefit because the treatment lowered RLS symptoms and reduced waking during the night, which can help with fatigue and daily energy. Caregivers should know this option could mean fewer nighttime disruptions and less need to help with sleep-related discomfort. Doctors and nurses treating MS might consider this as another option, especially when standard drugs cause side effects or make RLS worse over time. Think of it like trying a different sleep tool when a regular one stops working: this medicine works a different way and helped many in the study. Patients with mild to moderate MS and clear RLS symptoms are the most similar to the people in this study and are the best match for these results.

Important Considerations

This was a small, open-label study without a placebo group, so people knew they were getting the medicine and that can affect how they report symptoms. Most participants had mild to moderate MS, so results may not be the same for people with severe disability or other health issues. The study shows promise, but larger and controlled trials are needed before we can be sure how well and how safely this works for everyone.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Specific Symptoms Living with MS

Article Topics:

Augmentation syndromeCannabinoidsRLSRLS treatment

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News